Moving to the Next Level in Biomanufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Moving to the Next Level in Biomanufacturing
Growth in the market for monoclonal antibodies, recombinant proteins, and vaccines creates new opportunities for drug companies and suppliers.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 64-70

Vaccines

Although vaccines are a relatively small part of the overall pharmaceutical market, they are part of the growth strategy of certain pharmaceutical majors such as sanofi-aventis, GlaxoSmithKline, Novartis, Merck & Co., and Pfizer via its recent acquisition of Wyeth (Madison, NJ). In an investor-relations presentation on vaccines in December 2009, sanofi aventis estimated the value of the vaccine market at EUR 15 billion ($21 billion) in 2008 and projected the market would reach EUR 23 billion ($32 billion) by 2013.

Private and public funding is helping to create opportunity in the vaccines market. Earlier this year, the Bill and Melinda Gates Foundation announced it will commit $10 billion during the next 10 years for research, development, and delivery of vaccines in poor and developing countries, which is in addition to $4.5 billion the foundation previously committed. The funding will be used to increase access to existing vaccines and support development for new vaccines for diseases such as malaria and tuberculosis. The Global Alliance for Vaccines and Immunization, a private–public partnership, is developing vaccines for diarrhea and pneumonia. This funding and high-profile government intervention into vaccine development as in the case of pandemic flu is transforming the vaccine sector from a traditionally lower-valued sector to a more value-added one.

Vaccines for meeting unmet medical needs commonly found in developing nations, as well as prophylactic vaccines such as cancer vaccines, have become important areas of research. For example, in March 2010, Novartis signed an option worth up to EUR 700 million ($950 million) with the biotechnology firm Transgene (Parc d' Innovation d'Illkirch, France) conditioned on the successful development of the cancer vaccine TG4010, which is being developed for non-small cell lung cancer. This type of vaccine research is another example of the evolving market opportunities in biologics.

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
.

References

1. F. Pavlou, C. Lawrence and S. Sutton, Pharm. Tech. Europe 22 (2), 20–21 (2010).

2. P. Van Arnum, Pharm. Technol. Sourcing and Management, Apr. 2009, http://PharmTech.com/, accessed Mar. 15, 2010.

3. P. Van Arnum, Pharm. Technol. 33 (8), 38–41 (2009).

4. P. Van Arnum Pharm.Technol. Sourcing and Management, Mar. 2010, http://PharmTech.com/, accessed Mar. 15, 2010.

5. F. Schwarz, Nature Chem. Bio. DOI:10.1038/nchembio.314 (2010).

6. S. Borman, Chem. Eng. News 88 (10), 11 (2010).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here